Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Early intervention in children and adolescents who experience delayed MTX-clearance and renal
dysfunction in ALL treatments with the enzyme Glucarpidase which rapidly hydrolyses MTX to
non-toxic metabolites to avoid life threatening complications.
Phase:
Phase 3
Details
Lead Sponsor:
Nordic Society for Pediatric Hematology and Oncology